{"filings":[{"id":805679,"accession_number":"0000950103-26-008321","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-06-02T20:01:37+00:00","items":["5.07","9.01"],"status":"ready","headline":"ADC Therapeutics shareholders approve capital range increase, equity plan expansion at 2026 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approved increase in authorized shares under 2019 Equity Incentive Plan: 46.6M for, 18.9M against.","Capital range expanded to CHF 10.4M lower / CHF 15.6M upper limit.","Conditional share capital for financing increased from 38.0M to 48.0M shares.","Board compensation capped at $2.5M; executive fixed $2.6M + variable $5.5M.","All nine director nominees reelected; all 12 proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95341,"accession_number":"0001628280-26-029524","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics Q1 net product revenue $20.0M, net loss $0.21/share; cash runway into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $20.0M (up 15% YoY from $17.4M).","Net loss $33.0M ($0.21/share) vs $38.6M ($0.36/share) in Q1 2025; adjusted net loss $19.7M ($0.13/share).","Cash $231.0M as of Mar 31, 2026; cash runway at least into 2028.","LOTIS-5 Phase 3 topline results expected Q2 2026; full data and LOTIS-7 data by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":20851000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108313,"accession_number":"0001628280-26-016238","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics posts Q4 revenue $22.3M; net loss narrows; LOTIS-5 topline data expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product revenue $22.3M, full year $73.6M, up from $16.4M and $69.3M respectively in 2024.","Q4 net loss $6.4M ($0.04/share) vs $30.7M ($0.29/share) in 2024; adjusted net loss $13.5M.","Cash and cash equivalents $261.3M; expected cash runway at least into 2028.","LOTIS-5 Phase 3 topline data in 2L+ DLBCL expected Q2 2026; LOTIS-7 full data by year-end 2026.","Amendment to HealthCare Royalty financing reduces change-of-control payment to $150M through 2027; warrants for 9.8M shares at $3.81."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108312,"accession_number":"0000950103-26-002466","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ADC Therapeutics cuts change-of-control payment to HCR from $750M to $150-200M; issues warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Under amended HCR agreement, change-of-control payment reduced to $150M before 2028 or $200M after, from $750M previously.","Post-change-of-control royalties continue unless bought out for $525M-$750M less payments already made.","ADC issued warrants to HCR for 9,834,776 common shares at $3.8130 per share, exercisable until Dec 31, 2030.","Warrants are non-transferable before Jan 1, 2028; registration statement to be filed within 30 business days.","HCR had already provided $300M under original 2021 agreement; amendment reduces ADC's near-term buyout risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108311,"accession_number":"0000950103-26-000349","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADC Therapeutics posts updated corporate presentation with no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["ADC Therapeutics made available an updated corporate presentation dated January 2026 via 8-K filing.","The presentation excerpt contains only forward-looking statements boilerplate; no specific financial data or events.","No changes to guidance, pipeline status, or leadership were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108310,"accession_number":"0001628280-26-001386","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ADC Therapeutics reports preliminary 2025 revenue of ~$73M; cash runway extended to 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2025 ZYNLONTA net product revenue ~$22M; full year 2025 ~$73M vs $69.3M in 2024.","Cash and cash equivalents ~$261M as of Dec 31, 2025; expected cash runway at least to 2028.","LOTIS-7 Phase 1b shows 89.8% ORR and 77.6% CR; enrollment completion expected H1 2026.","LOTIS-5 Phase 3 topline data expected in Q2 2026; potential sBLA and approval mid-2027 if positive.","IND-enabling activities completed for PSMA-targeting ADC; partnership opportunities being explored."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124765,"accession_number":"0000950103-25-015818","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ADC Therapeutics reports 89.8% ORR and 77.6% CR in LOTIS-7 trial of ZYNLONTA + glofitamab in r/r DLBCL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Best ORR 89.8% (44/49); CR rate 77.6% (38/49) across dose levels.","At 150 µg/kg dose, ORR 85.7% and CR 75.0%.","In primary refractory patients (n=25): ORR 80%, CR 64%.","Of 8 prior CAR-T patients, 6 achieved CR.","Grade 3+ neutropenia (32.7%); manageable safety profile overall."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124764,"accession_number":"0001628280-25-050796","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics Q3 net product revenue $15.8M; net loss narrows to $41M; $60M PIPE strengthens cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product revenue $15.8M (down 12% YoY); nine-month 2025 revenue $51.2M vs $52.9M in 2024.","Net loss $41.0M ($0.30 per share) vs $44.0M ($0.42) in Q3 2024; adjusted net loss $25.5M ($0.19).","Completed $60M PIPE financing with $57.6M net proceeds; pro forma cash $292.3M to support ZYNLONTA expansion.","LOTIS-7 updated data by end of 2025; LOTIS-5 topline data expected 1H 2026; FL IIT shows ORR 98.2%, CR 83.6%.","IND-enabling for PSMA-targeting ADC to be completed by end of 2025; restructuring costs $13.5M YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":58299000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124763,"accession_number":"0000950103-25-013103","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","2.02","3.02","9.01"],"status":"ready","headline":"ADC Therapeutics raises $60M PIPE; prelim Q3 ZYNLONTA revenue $15.8M, cash $234.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIPE of 11.25M shares at $4.00 and 3.85M pre-funded warrants at $3.90; gross $60M, close expected Oct 27.","Preliminary Q3 2025 ZYNLONTA net product revenue approximately $15.8M.","Cash and equivalents $234.7M as of Sep 30; pro forma $292.3M after PIPE net proceeds (~$57.6M).","PIPE led by TCGX with Redmile Group and other existing investors; Jefferies acted as placement agent.","Net proceeds to fund ZYNLONTA commercial expansion, strengthen balance sheet, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141454,"accession_number":"0000950103-25-012514","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADC Therapeutics updates with strong LOTIS-7 combo data; ZYNLONTA expansion plans detailed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LOTIS-7 (ZYNLONTA+glofitamab) achieved 86.7% CR rate in r/r LBCL; 93.3% ORR in evaluable patients (N=30).","LOTIS-5 Phase 3 trial fully enrolled; topline data expected 1H 2026 for potential sBLA submission.","ZYNLONTA Phase 2 IIT in r/r MZL showed 69.2% CR and 84.6% ORR (N=26 evaluable); CR maintained in 17/18 patients.","PSMA-targeting ADC progresses IND-enabling activities; seeking research collaborations.","Cash runway expected into 2028; company continues to grow ZYNLONTA revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141453,"accession_number":"0001771910-25-000006","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics Q2 net loss widens to $56.6M; completes $100M PIPE, cuts workforce 30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product revenue $18.1M (+6% YoY); net loss $56.6M ($0.50/share) vs $36.5M loss ($0.38) in Q2 2024.","Completed $100M PIPE with $93.1M net proceeds; cash $264.6M, expected runway into 2028.","LOTIS-7 (ZYNLONTA+glofitamab) showed 93.3% ORR, 86.7% CR in r/r DLBCL; expansion to 100 patients underway.","Strategic restructuring: discontinuing early solid tumor programs, shutting UK facility, workforce reduction ~30% by Sep 2025.","LOTIS-5 Phase 3 on track to reach PFS events by end of 2025; sBLA filing expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":41872000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159274,"accession_number":"0000950103-25-007282","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.01","2.05","3.02","9.01"],"status":"ready","headline":"ADC Therapeutics announces $100M private placement and restructuring with 30% workforce cut","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$100M private placement: 13.03M shares at $3.53 & 15.73M pre-funded warrants at $3.432; close June 16, 2025.","Board approved restructuring to focus on ZYNLONTA and PSMA ADC; discontinue early preclinical solid tumor programs.","UK R&D facility to shut down; global workforce reduced by ~30%; substantially complete by September 30, 2025.","Estimated one-time pre-tax restructuring charges of $6M-$7M, majority recognized in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159273,"accession_number":"0000950103-25-007061","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ADC Therapeutics elects Timothy Coughlin to board at 2025 AGM; all proposals pass","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Coughlin elected to board; CPA, former Neurocrine CFO, appointed audit committee chair.","Binding votes: board max comp $2.3M, exec fixed $2.6M, variable $3.5M.","Amendment to 2019 Equity Incentive Plan approved to increase authorized shares.","Articles of association amended to raise conditional share capital for employee participation.","All 12 shareholder proposals, including director elections and say-on-pay, approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159272,"accession_number":"0001628280-25-025329","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics Q1 net loss narrows to $38.6M; ZYNLONTA revenue $17.4M, LOTIS-7 shows 95.5% ORR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product revenue $17.4M vs $17.8M YoY; license revenue $5.6M including $5M Canadian milestone.","Net loss $38.6M ($0.36/sh) vs $46.6M ($0.56); adjusted net loss $24.0M ($0.22).","Cash $194.7M at March 31; runway expected into H2 2026.","LOTIS-7 (ZYNLONTA+glofitamab) enrolled 40 patients; abstract shows 95.5% ORR, 90.9% CR.","LOTIS-5 confirmatory trial on track for PFS events by end of 2025; ADCT-602 discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":23033000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177704,"accession_number":"0001628280-25-015057","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics reports Q4/FY2024 results: net loss narrows; ZYNLONTA revenue flat; cash runway to H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 was $30.7M ($0.29/share) vs $85.0M ($1.03) in Q4 2023; full year net loss $157.8M ($1.62) vs $240.1M ($2.94).","ZYNLONTA net product revenue $16.4M in Q4 and $69.3M for FY 2024, roughly flat vs prior year.","Cash $250.9M at Dec 31, 2024; runway into H2 2026 after $97.4M May 2024 offering.","LOTIS-5 Phase 3 confirmatory trial enrollment completed Dec 2024; data update expected late 2025.","LOTIS-7 Phase 1b: 94% best ORR and 72% CR in r/r DLBCL; dose expansion enrollment completing Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177703,"accession_number":"0000950103-25-000411","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ADC Therapeutics releases preliminary 2024 ZYNLONTA sales and expense data at JPM conference","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Preliminary ZYNLONTA net sales and FY2024 expenses disclosed at JPMorgan Healthcare Conference; no specific figures in filing.","Forward-looking statements reference expected cash runway into mid-2026 and potential to grow ZYNLONTA revenue.","Presentation highlights pipeline including LOTIS 5, LOTIS 7, ADCT-602, and exatecan-based solid tumor platform.","ZYNLONTA is approved for relapsed/refractory large B-cell lymphoma after two prior therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":70837000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194424,"accession_number":"0000950103-24-016242","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ADC Therapeutics shareholders approve capital range increase and conditional share capital amendments","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved amendment to Article 4a to increase capital range (52.4M for, 9.0M against).","Shareholders approved amendment to Article 4c to increase conditional share capital for financing/acquisitions (52.3M for, 9.0M against).","Amendments to articles of association became effective immediately upon approval at Nov 11, 2024 special meeting.","Broker non-votes: none reported for either proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194423,"accession_number":"0001628280-24-045995","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics reports Q3 2024 revenue $18.0M; net loss narrows; discontinues ADCT-601","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZYNLONTA net product revenue $18.0M in Q3 2024 vs $14.3M in Q3 2023; year-to-date $52.9M.","Net loss $44.0M ($0.42 per share) in Q3 2024 vs $46.7M ($0.57) in Q3 2023; adjusted net loss $29.4M.","Cash and cash equivalents $274.3M as of Sep 30, 2024; expected runway into mid-2026.","Discontinued ADCT-601 (AXL-targeting) due to unfavorable benefit-risk; prioritizing exatecan-based ADC platform.","LOTIS-5 Phase 3 trial (ZYNLONTA+rituximab) full enrollment expected by year-end 2024; LOTIS-7 data update in Dec 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":53927000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210744,"accession_number":"0001628280-24-034975","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics Q2 2024: ZYNLONTA $17M (−5% QoQ), net loss $36.5M, cash extended to mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZYNLONTA net sales $17.0M in Q2 2024 (−5% QoQ, −11% YoY); commercial profitability achieved.","Net loss $36.5M ($0.38/sh) vs $48.9M ($0.60/sh) in Q2 2023; adjusted net loss $24.4M ($0.25/sh).","Cash $300.1M after $97.4M May 2024 offering; runway extended into mid-2026.","LOTIS-5 Phase 3 IDMC recommended continue; full enrollment expected before year-end 2024.","LOTIS-7 dose expansion on track; safety/efficacy data expected year-end 2024, mature data H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":35463000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229134,"accession_number":"0000950103-24-008385","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ADC Therapeutics shareholders approve all 12 proposals at 2024 AGM, including director re-elections and compensation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved management report, annual financial statements, and discharge of directors/executive committee for FY2023.","All nine directors reelected; compensation committee members, independent proxy, and PwC auditors also reelected.","Binding approval: board comp cap $2M; fixed exec comp cap $3M (FY2025); variable exec comp cap $10M (FY2024).","Advisory votes: compensation report and say-on-pay passed; shareholders recommended annual frequency, adopted by company.","Articles of association amended in six areas including shareholder rights, meetings, and conditional share capital flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229133,"accession_number":"0000950103-24-006646","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADC Therapeutics posts corporate presentation; no material new disclosures identified","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated May 14, 2024 made available for industry conferences and investor meetings.","No specific financial or operational metrics disclosed in the 8-K or exhibit summary.","Presentation contains forward-looking statements; limited detail on pipeline or guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229132,"accession_number":"0000950103-24-006462","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADC Therapeutics raises ~$105M in public offering of common shares and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 13.4M common shares at $4.90/share and pre-funded warrants for 8.2M shares at $4.812/warrant.","Gross proceeds ~$105M; underwriters include Jefferies, Guggenheim, Cantor Fitzgerald; offering closed May 8, 2024.","Pre-funded warrants exercisable at CHF 0.08/share, with a 9.99% beneficial ownership cap (adjustable to 19.99%).","Warrants have a 10-year term and may be exercised on a cashless basis under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229131,"accession_number":"0001628280-24-020447","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ADC Therapeutics Q1 net loss narrows to $46.6M; ZYNLONTA sales $17.8M; initial MZL data shows 13/15 CR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZYNLONTA net sales $17.8M in Q1 2024, up 7% QoQ, down 6% YoY; total operating expenses down 25%.","Net loss $46.6M ($0.56/share) vs $59.4M ($0.73) in Q1 2023; adjusted net loss $31.1M.","Cash $234.3M as of Mar 31, 2024; cash runway expected into Q4 2025.","LOTIS-5 enrollment on track to complete in 2024; LOTIS-7 dose escalation complete, expansion initiated.","Initial Phase 2 IIT data in r/r MZL: 15 evaluable patients, 13 complete responses (CR) and 1 PR."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":18053000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}